Journal of Gastric Cancer最新文献_第8页

Current Issues in Reduced-Port Gastrectomy: A Comprehensive Review. 减孔胃切除术的当前问题：全面回顾。

IF 2.5 4区医学

Journal of Gastric Cancer Pub Date : 2024-01-01 DOI: 10.5230/jgc.2024.24.e9

Jong Won Kim

{"title":"Current Issues in Reduced-Port Gastrectomy: A Comprehensive Review.","authors":"Jong Won Kim","doi":"10.5230/jgc.2024.24.e9","DOIUrl":"10.5230/jgc.2024.24.e9","url":null,"abstract":"Reduced-port gastrectomy (RPG) includes all procedures derived from various efforts to minimize surgical invasiveness, with single-incision laparoscopic gastrectomy (SILG) being the ultimate reduced-port technique. However, there are challenges related to its feasibility, oncological validity, training, and education. This review describes the current issues and challenges, as well as the future prospects of RPG for gastric cancer. Gastrectomy, which started as an open surgery, has evolved into a laparoscopic surgery. With the advancements in laparoscopic technology, SILG has been used to minimize surgical scarring. However, owing to the technical difficulties of SILG, cases involving the addition of 1 trocar or needle grasper alongside the multichannel port have also been reported. Additionally, 3-port laparoscopic gastrectomy (3PLG) using only 3 trocars is also being performed. RPG, as a concept, includes a range of approaches such as SILG, 2-port laparoscopic gastrectomy, and 3PLG. These techniques aimed to reduce the number of ports or incisions required for laparoscopic gastrectomy. Despite technical difficulties, RPGs offer numerous advantages, including minimal invasiveness, excellent cosmetic outcomes, and the potential for improved post-operative recovery, such as reduced length of hospital stay and post-operative pain. It could be considered similar to conventional laparoscopic gastrectomy, and may not be oncologically inferior. Ongoing studies, such as the KLASS 12, are required to gain further insights.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"24 1","pages":"57-68"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139473049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk Factors of Gastric Cancer and Lifestyle Modification for Prevention. 胃癌的风险因素和预防胃癌的生活方式改变。

IF 2.5 4区医学

Journal of Gastric Cancer Pub Date : 2024-01-01 DOI: 10.5230/jgc.2024.24.e10

Kwang-Pil Ko

{"title":"Risk Factors of Gastric Cancer and Lifestyle Modification for Prevention.","authors":"Kwang-Pil Ko","doi":"10.5230/jgc.2024.24.e10","DOIUrl":"10.5230/jgc.2024.24.e10","url":null,"abstract":"Gastric cancer has been consistently decreasing worldwide, whereas cardia gastric cancer is on the rise. This indicates that the exposure rates to epidemiological causes are changing. In this study, we aim to review the risk factors for gastric cancer with respect to cardia and non-cardia types. One of the most significant risk factors for gastric cancer is Helicobacter pylori infection. H. pylori infection is known as a risk factor for non-cardia gastric cancer, and there have been results indicating that H. pylori infection is not associated with cardia gastric cancer. However, in the East Asian region, there is epidemiological evidence suggesting that H. pylori infection might be a risk factor for cardia gastric cancer. Smoking and alcohol consumption are known risk factors for gastric cancer, regardless of anatomical location. Obesity is considered a factor in the development of cardia gastric cancer. However, further research is needed to understand the specific relationship with non-cardia gastric cancer. The consumption of high-salt and processed meat is more distinctly associated with non-cardia gastric cancer than in cardia gastric cancer. In addition to these factors, exposure to chemicals and radiation are considered risk factors for gastric cancer. Primary prevention of gastric cancer involves eliminating or avoiding risk factors such as H. pylori eradication and adopting a healthy lifestyle, including quitting smoking, reducing alcohol consumption, maintaining a healthy weight, and having a low-salt diet.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"24 1","pages":"99-107"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139473081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Latest Insights From Multiple Disciplinary Approaches to Manage Gastric Cancer. 多学科方法治疗胃癌的最新见解。

IF 3.2 4区医学

Journal of Gastric Cancer Pub Date : 2024-01-01 DOI: 10.5230/jgc.2024.24.e8

Ki Bum Park, Han Hong Lee

引用次数: 0

Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond. 胃癌全身治疗的新靶点：HER2 及其他

IF 3.2 4区医学

Journal of Gastric Cancer Pub Date : 2024-01-01 DOI: 10.5230/jgc.2024.24.e6

In-Ho Kim

{"title":"Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond.","authors":"In-Ho Kim","doi":"10.5230/jgc.2024.24.e6","DOIUrl":"10.5230/jgc.2024.24.e6","url":null,"abstract":"In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug conjugates, have once again brought attention to anti-HER2 targeted treatments. In HER2-negative diseases, the combination of cytotoxic chemotherapy and programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors has become the established standard of care in first-line settings. In the context of gastric cancer, potential biomarkers such as PD-L1 expression, Epstein-Barr virus, microsatellite instability, and tumor mutational burden are being considered for immunotherapy. Recently, promising results have been reported in studies on anti-Claudin18.2 and fibroblast growth factor receptor 2 treatments. Currently, many ongoing trials are aimed at identifying potential targets using novel approaches. Further investigations will be conducted to enhance the progress of these therapies, addressing challenges such as primary and acquired resistance, tumor heterogeneity, and clonal evolution. We believe that these efforts will improve patient prognoses. Herein, we discuss the current evidence of potential targets for systemic treatment, clinical considerations, and future perspectives.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"24 1","pages":"29-56"},"PeriodicalIF":3.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139473052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endoscopic Treatment for Gastric Subepithelial Tumor. 胃上皮下瘤的内窥镜治疗。

IF 2.5 4区医学

Journal of Gastric Cancer Pub Date : 2024-01-01 DOI: 10.5230/jgc.2024.24.e11

Chan Gyoo Kim

{"title":"Endoscopic Treatment for Gastric Subepithelial Tumor.","authors":"Chan Gyoo Kim","doi":"10.5230/jgc.2024.24.e11","DOIUrl":"10.5230/jgc.2024.24.e11","url":null,"abstract":"Most gastric subepithelial tumors (SETs) are asymptomatic and are often incidentally discovered during endoscopic procedures conducted for unrelated reasons. Although surveillance is sufficient for the majority of gastric SETs, certain cases necessitate proactive management. Laparoscopic wedge resection, although a viable treatment option, has its limitations, particularly in cases where SETs (especially those with intraluminal growth) are not visualized on the peritoneal side. Recent advances in endoscopic instruments and technology have paved the way for the feasibility of endoscopic resection of SETs. Several promising endoscopic techniques have emerged for gastric SET resection, including submucosal tunneling endoscopic resection, endoscopic full-thickness resection (EFTR), laparoscopic and endoscopic cooperative surgery (LECS), and non-exposure EFTR (non-exposed endoscopic wall-inversion surgery and non-exposure simple suturing EFTR). This study aimed to discuss the indications, methods, and outcomes of endoscopic therapy for gastric SETs. In addition, a simplified diagram of the category of SETs according to the therapeutic indications and an algorithm for the endoscopic management of SET is suggested.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"24 1","pages":"122-134"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139473059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liquid Biopsy: An Emerging Diagnostic, Prognostic, and Predictive Tool in Gastric Cancer. 液体活检：胃癌诊断、预后和预测的新兴工具

IF 2.5 4区医学

Journal of Gastric Cancer Pub Date : 2024-01-01 DOI: 10.5230/jgc.2024.24.e5

Hye Sook Han, Keun-Wook Lee

{"title":"Liquid Biopsy: An Emerging Diagnostic, Prognostic, and Predictive Tool in Gastric Cancer.","authors":"Hye Sook Han, Keun-Wook Lee","doi":"10.5230/jgc.2024.24.e5","DOIUrl":"10.5230/jgc.2024.24.e5","url":null,"abstract":"Liquid biopsy, a minimally invasive procedure that causes minimal pain and complication risks to patients, has been extensively studied for cancer diagnosis and treatment. Moreover, it facilitates comprehensive quantification and serial assessment of the whole-body tumor burden. Several biosources obtained through liquid biopsy have been studied as important biomarkers for establishing early diagnosis, monitoring minimal residual disease, and predicting the prognosis and response to treatment in patients with cancer. Although the clinical application of liquid biopsy in gastric cancer is not as robust as that in other cancers, biomarker studies using liquid biopsy are being actively conducted in patients with gastric cancer. Herein, we aimed to review the role of various biosources that can be obtained from patients with gastric cancer through liquid biopsies, such as blood, saliva, gastric juice, urine, stool, peritoneal lavage fluid, and ascites, by dividing them into cellular and acellular components. In addition, we reviewed previous studies on the diagnostic, prognostic, and predictive biomarkers for gastric cancer using liquid biopsy and discussed the limitations of liquid biopsy and the challenges to overcome these limitations in patients with gastric cancer.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"24 1","pages":"4-28"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139473073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unusual or Uncommon Histology of Gastric Cancer. 胃癌的异常或不常见组织学。

IF 2.5 4区医学

Journal of Gastric Cancer Pub Date : 2024-01-01 DOI: 10.5230/jgc.2024.24.e7

Jinho Shin, Young Soo Park

{"title":"Unusual or Uncommon Histology of Gastric Cancer.","authors":"Jinho Shin, Young Soo Park","doi":"10.5230/jgc.2024.24.e7","DOIUrl":"10.5230/jgc.2024.24.e7","url":null,"abstract":"This review comprehensively examines the diverse spectrum of gastric cancers, focusing on unusual or uncommon histology that presents significant diagnostic and therapeutic challenges. While the predominant form, tubular adenocarcinoma, is well-characterized, this review focuses on lesser-known variants, including papillary adenocarcinoma, micropapillary carcinoma, adenosquamous carcinoma, squamous cell carcinoma (SCC), hepatoid adenocarcinoma, gastric choriocarcinoma, gastric carcinoma with lymphoid stroma, carcinosarcoma, gastroblastoma, parietal cell carcinoma, oncocytic adenocarcinoma, Paneth cell carcinoma, gastric adenocarcinoma of the fundic gland type, undifferentiated carcinoma, and extremely well-differentiated adenocarcinoma. Although these diseases have different nomenclatures characterized by distinct histopathological features, these phenotypes often overlap, making it difficult to draw clear boundaries. Furthermore, the number of cases was limited, and the unique histopathological nature and potential pathogenic mechanisms were not well defined. This review highlights the importance of understanding these rare variants for accurate diagnosis, effective treatment planning, and improving patient outcomes. This review emphasizes the need for ongoing research and case studies to enhance our knowledge of these uncommon forms of gastric cancer, which will ultimately contribute to more effective treatments and better prognostic assessments. This review aimed to broaden the pathological narrative by acknowledging and addressing the intricacies of all cancer types, regardless of their rarity, to advance patient care and improve prognosis.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"24 1","pages":"69-88"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139473086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study. Trastuzumab Deruxtecan和Nivolumab作为HER2阳性晚期癌症的三线或二线治疗的有效性和安全性：一项单一机构回顾性研究。

IF 2.5 4区医学

Journal of Gastric Cancer Pub Date : 2023-10-01 DOI: 10.5230/jgc.2023.23.e41

Keitaro Shimozaki, Izuma Nakayama, Daisuke Takahari, Kengo Nagashima, Koichiro Yoshino, Koshiro Fukuda, Shota Fukuoka, Hiroki Osumi, Mariko Ogura, Takeru Wakatsuki, Akira Ooki, Eiji Shinozaki, Keisho Chin, Kensei Yamaguchi

{"title":"Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study.","authors":"Keitaro Shimozaki, Izuma Nakayama, Daisuke Takahari, Kengo Nagashima, Koichiro Yoshino, Koshiro Fukuda, Shota Fukuoka, Hiroki Osumi, Mariko Ogura, Takeru Wakatsuki, Akira Ooki, Eiji Shinozaki, Keisho Chin, Kensei Yamaguchi","doi":"10.5230/jgc.2023.23.e41","DOIUrl":"10.5230/jgc.2023.23.e41","url":null,"abstract":"Purpose Determination of optimal treatment strategies for HER2-positive advanced gastric cancer (AGC) in randomized trials is necessary despite difficulties in direct comparison between trastuzumab deruxtecan (T-DXd) and nivolumab as third or later-line treatments. Materials and Methods This single-institution, retrospective study aimed to describe the real-world efficacy and safety of T-DXd and nivolumab as ≥ third line treatments for HER2-positive AGC between March 2016 and May 2022. Overall, 58 patients (median age, 64 years; 69% male) were eligible for the study (T-DXd group, n=20; nivolumab group, n=38). Results Most patients exhibited a HER2 3+ status (72%) and presented metastatic disease at diagnosis (66%). The response rates of 41 patients with measurable lesions in the T-DXd and nivolumab groups were 50% and 15%, respectively. The T-DXd and nivolumab groups had a median progression-free survival of 4.8 months (95% confidence interval [CI], 3.3, 7.0) and 2.3 months (95% CI, 1.5, 3.5), median overall survival (OS) of 10.8 months (95% CI, 6.9, 23.8) and 11.7 months (95% CI, 7.6, 17.1), and grade 3 or greater adverse event rates of 50% and 2%, respectively. Overall, 64% patients received subsequent treatment. Among 23 patients who received both regimens, the T-DXd–nivolumab and nivolumab–T-DXd groups had a median OS of 14.0 months (95% CI, 5.0, not reached) and 19.3 months (95% CI, 9.5, 25.1), respectively. Conclusions T-DXd and nivolumab showed distinct efficacy and toxicity profiles as ≥ third line treatments for HER2-positive AGC. Considering the distinct features of each regimen, they may help clinicians personalize optimal treatment approaches for these patients.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 4","pages":"609-621"},"PeriodicalIF":2.5,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Clean End-to-End Anastomosis Method, Without Opening the Stomach Lumen, in Totally Laparoscopic or Robotic Pylorus-Preserving Gastrectomy. 在完全腹腔镜或机器人保胃胃切除术中，无需打开胃腔的新型端到端清洁吻合方法。

IF 2.5 4区医学

Journal of Gastric Cancer Pub Date : 2023-10-01 DOI: 10.5230/jgc.2023.23.e33

Takashi Mitsui, Kazuyuki Saito, Yuhei Hakozaki, Yoshiyuki Miwa, Takuji Noro, Emiko Takeshita, Taizen Urahashi, Yasuyuki Seto, Takashi Okuyama, Hideyuki Yoshitomi

{"title":"Novel Clean End-to-End Anastomosis Method, Without Opening the Stomach Lumen, in Totally Laparoscopic or Robotic Pylorus-Preserving Gastrectomy.","authors":"Takashi Mitsui, Kazuyuki Saito, Yuhei Hakozaki, Yoshiyuki Miwa, Takuji Noro, Emiko Takeshita, Taizen Urahashi, Yasuyuki Seto, Takashi Okuyama, Hideyuki Yoshitomi","doi":"10.5230/jgc.2023.23.e33","DOIUrl":"10.5230/jgc.2023.23.e33","url":null,"abstract":"Purpose: Intra-abdominal infection is a common postoperative complication of laparoscopic pylorus-preserving gastrectomies (PPGs). Many studies have reported that intra-abdominal infectious complications after gastrectomy adversely affect patient survival outcomes. To prevent gastric fluid leakage into the abdominal cavity, we developed a novel anastomosis method in which the stomach lumen is not opened (termed the non-opened clean end-to-end anastomosis method [NoCEAM]) and evaluated its feasibility.Materials and methods: Subsequent to lymphadenectomy, the oral and anal resection lines were sutured using an intraoperative endoscope. After closing the stomach circumferentially with clips, the specimen was rolled outward like a \"donut.\" We resected the specimen circumferentially using a linear stapler, and anastomosis was completed simultaneously. We examined the feasibility of this procedure ex vivo, using three porcine stomachs, and in vivo, using one pig. Subsequently, we applied the procedure to 13 consecutive patients with middle-third early gastric cancer utilizing laparotomic, laparoscopic, and robotic PPG.Results: NoCEAM was completed in all porcine models and human cases. In the human cases, the mean operation time (±standard deviation) was 279±51 minutes, and mean blood loss volume was 22±45 mL. The mean number of linear staples used was 5.06±0.76. None of the patients had complications, and all were discharged on the eighth postoperative. The serum total protein, serum albumin, and hemoglobin levels did not change significantly after surgery.Conclusions: NoCEAM is feasible and safe for performing totally laparoscopic or robotic PPG. It may reduce postoperative complications, such as intra-abdominal infections.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 4","pages":"523-534"},"PeriodicalIF":2.5,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Indications for Dental Floss Clip Traction During Gastric Endoscopic Submucosal Dissection by Less-Experienced Endoscopists. 经验不足的内窥镜医生在胃内窥镜粘膜下解剖过程中牙线夹牵引的适应症。

IF 3.8 4区医学

Journal of Gastric Cancer Pub Date : 2023-10-01 DOI: 10.5230/jgc.2023.23.e37

Hirosato Tamari, Shiro Oka, Takahiro Kotachi, Hajime Teshima, Junichi Mizuno, Motomitsu Fukuhara, Hidenori Tanaka, Akiyoshi Tsuboi, Ken Yamashita, Ryo Yuge, Yuji Urabe, Yasuhiko Kitadai, Koji Arihiro, Shinji Tanaka

{"title":"Indications for Dental Floss Clip Traction During Gastric Endoscopic Submucosal Dissection by Less-Experienced Endoscopists.","authors":"Hirosato Tamari, Shiro Oka, Takahiro Kotachi, Hajime Teshima, Junichi Mizuno, Motomitsu Fukuhara, Hidenori Tanaka, Akiyoshi Tsuboi, Ken Yamashita, Ryo Yuge, Yuji Urabe, Yasuhiko Kitadai, Koji Arihiro, Shinji Tanaka","doi":"10.5230/jgc.2023.23.e37","DOIUrl":"10.5230/jgc.2023.23.e37","url":null,"abstract":"Purpose: Dental floss clip (DFC) traction-assisted endoscopic submucosal dissection (ESD) is widely performed owing to its simplicity. This study aimed to clarify the appropriate indications for the DFC traction method in early gastric cancer when ESD is performed by less-experienced endoscopists.Methods and methods: We retrospectively analyzed 1,014 consecutive patients who had undergone gastric ESD performed by less-experienced endoscopists between January 2015 and December 2020. Gastric ESD was performed without DFC in all cases before December 2017 [DFC (-) group, 376 cases], and ESD was performed with DFC in all cases after January 2018 [DFC (+) group, 436 cases]. The procedure time and rates of en bloc resection, complete resection, and adverse events of the groups were compared.Results: The procedure time did not differ significantly between the 2 groups. However, when comparing lesions >20 mm, the procedure time in the DFC (+) group was significantly shorter than that in the DFC (-) group (95±46 vs. 75±31, P<0.01). The procedure time for lesions located in the greater curvature of the upper or middle stomach and lesions >20 mm located in the lesser curvature side of the stomach in the DFC (+) group was significantly shorter than that in the DFC (-) group.Conclusions: The indications for DFC during gastric ESD by less-experienced endoscopists include lesions located in the greater curvature of the upper or middle stomach, and lesions >20 mm located in the lesser curvature of the stomach.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 4","pages":"512-522"},"PeriodicalIF":3.8,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0